INM — InMed Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.61m
- $0.15m
- $4.60m
- 24
- 64
- 25
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.58 | ||
| Price to Tang. Book | 0.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -117.23% | ||
| Return on Equity | -83.5% | ||
| Operating Margin | -162.82% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.09 | 4.14 | 4.6 | 7.03 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Directors
- William Garner NEC (55)
- Eric Adams PRE (58)
- Bruce Colwill CFO
- Alexandra Mancini SVP
- Adam Cutler IND (47)
- Andrew Hull IND (58)
- Catherine Sazdanoff IND (65)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 19th, 1981
- Public Since
- June 21st, 2001
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,207,186
- Address
- 1445-885 West Georgia St., VANCOUVER, V6C 3E8
- Web
- https://www.inmedpharma.com/
- Phone
- +1 6046697207
- Auditors
- Marcum LLP
Upcoming Events for INM
InMed Pharmaceuticals Inc Extraordinary Shareholders Meeting
Q4 2025 InMed Pharmaceuticals Inc Earnings Release
Similar to INM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the InMed Pharmaceuticals share price?
As of Today at 03:18 UTC, shares in InMed Pharmaceuticals are trading at $2.99. This share price information is delayed by 15 minutes.
How has the InMed Pharmaceuticals share price performed this year?
Shares in InMed Pharmaceuticals last closed at $2.99 and the price had moved by -40.67% over the past 365 days. In terms of relative price strength the InMed Pharmaceuticals share price has underperformed the S&P500 Index by -45.24% over the past year.
What are the analyst and broker recommendations for InMed Pharmaceuticals?
The overall consensus recommendation for InMed Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the InMed Pharmaceuticals dividend yield?
InMed Pharmaceuticals does not currently pay a dividend.
Does InMed Pharmaceuticals pay a dividend?
InMed Pharmaceuticals does not currently pay a dividend.
When does InMed Pharmaceuticals next pay dividends?
InMed Pharmaceuticals does not currently pay a dividend.
How do I buy InMed Pharmaceuticals shares?
To buy shares in InMed Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of InMed Pharmaceuticals?
As of the previous close price of $2.99, shares in InMed Pharmaceuticals had a market capitalisation of $3.61m.
Where are InMed Pharmaceuticals shares listed?
Here are the trading details for InMed Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INM
What kind of share is InMed Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum InMed Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a InMed Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in InMed Pharmaceuticals is $19.63. That is 556.39% above the last closing price of $2.99.
Analysts covering InMed Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the InMed Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InMed Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -52.7%.
As of the last closing price of $2.99, shares in InMed Pharmaceuticals were trading -29.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the InMed Pharmaceuticals PE Ratio?
The InMed Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of InMed Pharmaceuticals?
InMed Pharmaceuticals' management team is headed by:
- William Garner - NEC
- Eric Adams - PRE
- Bruce Colwill - CFO
- Alexandra Mancini - SVP
- Adam Cutler - IND
- Andrew Hull - IND
- Catherine Sazdanoff - IND